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Autologous T-cell therapy in SOT recipients with recurrent or drug-resistant CMV-associated 
complications is safe and may provide clinical benefit, especially when standard therapies are not 
effective or are contraindicated.  
 
Abstract 
Background  
Opportunistic infections including cytomegalovirus (CMV) are a major cause of morbidity and 
mortality in solid organ transplant (SOT) recipients. The recurrent and protracted use of anti-viral 
drugs with eventual emergence of drug resistance represents a significant constraint to therapy. 
While adoptive T-cell therapy has been successfully used in haematopoietic stem cell transplant 
recipients, its extension to the SOT setting poses a considerable challenge because of the inhibitory 
effects of immunosuppressive drugs on the virus-specific T-cell response in vivo, and the perceived 
risk of graft rejection.  
Methods  
In this prospective study, 22 SOT recipients (13 renal, 8 lung and 1 heart) with recurrent or 
ganciclovir-resistant CMV infection were recruited and of these, 13 patients were treated with in 
vitro-expanded autologous CMV-specific T cells. These patients were monitored for safety, clinical 
symptoms and immune reconstitution.  
Results 
Autologous CMV-specific T-cell manufacture was attempted for 21 patients, and was successful in 20 
cases. The use of this adoptive immunotherapy was associated with no therapy-related serious 
adverse events. Eleven (84%) of the thirteen treated patients showed improvement in symptoms, 
including complete resolution or reduction in DNAemia, CMV-associated end organ disease and/or 
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the cessation or reduced use of anti-viral drugs. Furthermore, many of these patients showed co-
incident increased frequency of CMV-specific T cells in peripheral blood following completion of T-
cell therapy. 
Conclusions 
The data presented here demonstrate for the first time the clinical safety of CMV-specific adoptive 
T-cell therapy and its potential therapeutic benefit for SOT patients with recurrent and/or drug-
resistant CMV infection or disease. 
Key words: immunotherapy, T cells, virus infection, transplant, cytomegalovirus 
Introduction 
 
Clinical management of cytomegalovirus (CMV) infection in solid organ transplant (SOT) recipients 
remains a major challenge. The incidence of early CMV-associated complications in SOT recipients 
has significantly reduced since the advent of virostatic therapy based on ganciclovir [1]. The 
inhibition of viral reactivation by either the prophylactic or pre-emptive administration of ganciclovir 
has therefore become critical in the prevention of CMV-associated disease. However, late CMV 
reactivation can be more problematic to manage, especially in patients who are unable to 
reconstitute anti-viral T cell immunity [2].  Furthermore, the emergence of ganciclovir-resistant CMV 
reactivation or disease poses major difficulties in clinical management, with significant morbidity 
and mortality due to drug-associated toxicity, immunomodulatory impact and allograft loss [3].  
Alternative safe and effective therapeutic options for ganciclovir-resistant CMV are lacking.  
Additional anti-viral management strategies, using foscarnet or cidofovir, are associated with 
nephrotoxicity, and require intravenous administration and hospitalisation. Genes conferring 
resistance to ganciclovir are also associated with resistance to foscarnet and cidofovir.  Newer 
antiviral therapeutics such as maribavir and letermovir may offer alternatives for the treatment of 
CMV, with the potential for reduced side-effects [4, 5]. Reduction in immunosuppression can be 
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used to improve viral control, but increases the risk of graft rejection. Over the last decade, a 
number of immune-based diagnostic tests have been developed which can help to identify patients 
who are at increased risk of developing early or late CMV-associated complications [6]. These studies 
have clearly shown that the reconstitution of anti-viral T-cell immunity is absolutely critical in 
protecting SOT recipients from CMV infection or reactivation [7-9].  
 The reconstitution of CMV immunity through the administration of CMV-specific T cells 
offers an attractive option to enhance the control of CMV in SOT recipients. This approach has been 
used very effectively to treat CMV-associated complications in haematopoietic stem cell transplant 
(HSCT) recipients. However, this is typically dependent upon the use of HSCT donor-derived material 
to generate CMV-specific cell therapy, whereas in the context of SOT recipients, autologous immune 
cells from heavily immunosuppressed individuals are required to generate an effective T-cell 
therapy.  Whilst showing some promising results with an autologous CMV-specific T-cell therapy in 
an SOT patient, a previous case study also raised potential safety concerns [10]. As a consequence, 
the development of this approach has been limited due to the perceived difficulties in generating T 
cells from highly immunosuppressed SOT recipients, and the potential risks associated with graft 
rejection following T-cell administration. Despite these concerns, we recently demonstrated in case 
reports the use of autologous T-cell therapies for CMV disease in two transplant recipients with no 
evident side effects [11, 12]  As a consequence of these promising results, we initiated a formal 
phase I study to assess the safety of autologous therapy in a larger cohort of lung, heart and kidney 
transplant recipients with CMV-associated complications. We demonstrate here the capacity to 
generate CMV-specific T cells from the majority of recruited SOT recipients despite these underlying 
complications. Following adoptive immunotherapy, we detected only grade 1 and 2 adverse events 
potentially associated with T-cell infusion, and saw no evidence for any impact on graft function or 
survival. More importantly, the majority of the patients showed resolution of clinical symptoms, 
which was coincident with anti-viral T-cell reconstitution in a proportion of the treated patients.  
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Materials and Methods 
Patient recruitment and study design 
This single-arm open-label phase I study was performed according to the principles of the 
Declaration of Helsinki and approved by the QIMR Berghofer Medical Research Institute Human 
Research Ethics Committee, The Prince Charles Hospital Human Research Ethics Committee and the 
Royal Adelaide Hospital Research Ethics Committee. This study was registered under the Australian 
New Zealand Clinical Trial Registry (ACTRN12613000981729).  Patients were deemed eligible for the 
study if they met at least one of the four following criteria:  (A) CMV reactivation or disease (as 
defined by histology) following successful initial therapy; (B) Persistent CMV disease, i.e. no response 
to 2 weeks of salvage foscarnet or other second-line anti-viral agent; (C) Persistent CMV replication 
(more than 6 weeks by PCR) despite appropriate anti-viral therapy; or (D) Any CMV reactivation or 
disease where anti-viral therapy is contraindicated on the basis of intolerance or end organ 
limitation (e.g. renal impairment, marrow dysfunction). CMV disease refers to organ dysfunction due 
to CMV infection and/or evidence of tissue invasive viral infection. Anti-viral drug therapy was 
administered as per the institutional guidelines. Standard prophylaxis for lung transplant recipients 
was valganciclovir until 9 months post-transplant. CMV IgG and lifelong valganciclovir was 
administered to D+R- lung transplant patients. Standard prophylaxis for renal transplant recipients 
included 3 months of valganciclovir for D+R+ and D-R+ patients, 6 months of valganciclovir for D+R- 
patients, and no treatment for D-R- patients. Standard prophylaxis for heart transplant recipients 
was valganciclovir until 6 months post-transplant for D+R+ patients, valganciclovir until 12 months 
for D+R- patients, and valacyclovir for D-R- patients. Patients received up to six doses of in vitro-
expanded T cells at 1‒2 × 107 cells/m2 at fortnightly intervals. Each participant was monitored for 
safety, clinical symptoms, viral load and immune reconstitution for 28 weeks after the completion of 
adoptive T-cell therapy. Viral load monitoring was undertaken using COBAS TaqMan PCR  assay 
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(Roche Molecular Diagnostics, Pleasanton, CA) as described previously [13]. The lower limit of 
detection in this assay is 150 copies/mL. 
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Manufacture and adoptive transfer of CMV-specific T cells 
To manufacture the CMV-specific T-cell therapy for each patient, peripheral blood mononuclear cells 
(PBMC) were stimulated with a clinical-grade custom peptide pool (JPT Technologies, Berlin, 
Germany) which includes pre-defined HLA class I and class II-restricted peptide epitopes from pp65, 
pp50, IE-1, gH and gB (Supplemental Table 1) [14-16]. These cells were cultured in Grex-10 culture 
flasks (Wilson Wolf Corporation, Saint Paul, MN) at a starting cell density of 2‒5 × 106 cells/cm2. 
These cultures were supplemented with recombinant IL-21 (40 ng/mL) on Day 0, and recombinant 
IL-2 (120 IU/mL) on Day 2 and every three days thereafter. On Day 14, expanded T cells were 
harvested and frozen in 1 mL single-dose aliquots in Albumex 4 (CSL Behring, Broadmeadows, 
Australia) containing 10% dimethyl sulfoxide (WAK-Chemie Medical GmbH, Steinbach, Germany). A 
dedicated good manufacturing practice-accredited cell therapy manufacturing facility (Q-Gen Cell 
Therapeutics) was used for T-cell therapy manufacturing and storage.  At the completion of in vitro 
culture, T cells were phenotypically and functionally characterised using Multitest 6-Colour TBNK 
Reagent (BD Biosciences, San Jose, CA) and intracellular cytokine staining (detailed below). 
Microbiological testing was performed as recommended under British Pharmacopoeia 2015 
(Appendices XVIE and XVIA) on all T-cell products, for the presence/absence of microbiological 
contamination (fungal and bacterial, including mycoplasma) and endotoxin (<3 EU/mL). For adoptive 
transfer, T cells were thawed into 19 mL clinical grade normal saline and infused intravenously over 
a period of 5‒10 min. 
 
Intracellular cytokine analysis of CMV-specific T cells  
To characterise the T-cell therapy and PBMC isolated from follow-up blood samples, cells were 
stimulated with CMV peptide epitopes and assessed for the expression of IFN-γ, TNF and IL-2, and 
mobilisation of CD107 using intracellular cytokine assay as described previously [17]. Cells were 
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acquired using a BD LSR Fortessa with FACSDiva software (BD Biosciences). Post-acquisition and 
Boolean analyses were performed using FlowJo software (FlowJo LLC, Ashland, OR). 
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Results 
Patient characteristics and T-cell therapy manufacturing 
The primary objective of this study was to assess the safety of autologous T-cell therapy in SOT 
recipients with CMV-associated complications. The clinical characteristics of the participants 
included in this study are provided in Table 1. CMV reactivation was managed in patients 
1553PAH06, 1553PAH08 and 1553PAH09 by a combination of antiviral therapy and reduction in 
immunosuppression prior to enrolment in the clinical trial. In total, 21 SOT recipients (13 renal, 8 
lung, 1 heart) were included in the study. Two of the lung transplant patients included in the follow-
up analyses were previously treated under the Special Access Scheme of the Therapeutic Goods 
Administration [11, 12].. Of the 21 patients analysed, 13 SOT recipients were allocated to 
intervention and received a maximum of six doses of adoptive T-cell therapy, whilst one patient 
discontinued therapy after a single dose and no immune monitoring was performed. Of the 
remaining eight patients, seven did not receive adoptive T-cell therapy due to improvement in their 
clinical status, and we failed to manufacture therapy for one patient.  
 CMV-specific T cells were successfully expanded from 20 of the 21 patients, and their 
antigen specificity was assessed by intracellular IFN-γ analysis (Table 2). The CMV peptide pool-
expanded cells were predominantly CD3+ CD8+ T cells (Fig 1A), with a median specificity of 51.2% (Fig 
1B). The frequency of IFN-γ-producing CD8+ T cells did not differ significantly between kidney and 
lung/heart transplant recipients (Fig. 1C) or pre-transplant CMV seropositive and CMV seronegative 
individuals (Fig. 1D). A marked improvement in the polyfunctionality of the CMV-specific T cells was 
observed following in vitro expansion, with an increase in the proportion of cells capable of 
producing IFN-γ, TNF and CD107a (Fig 1E). T cells generated from the majority of the patients 
showed reactivity against multiple peptide epitopes encoded by multiple CMV antigens (Table 2).   
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Clinical outcomes following adoptive immunotherapy 
None of the patients who received adoptive CMV-specific T-cell therapy showed treatment-related 
grade 3, 4 or 5 adverse events (Table 3 and Supp. Table 2). All adverse events that were deemed at 
least possibly attributable to T-cell infusion were grade 1 and 2, and included fatigue and malaise. 
Importantly, no adverse events associated with a change in the graft status were detected. Clinical 
follow-up of patients allocated to T-cell therapy intervention indicated that 11 of the 13 patients 
showed objective improvement in their symptoms. These included reduction or resolution of CMV 
reactivation and/or disease and improved response to anti-viral drug therapy. The median peak viral 
load prior to adoptive T-cell therapy in the 11 patients who showed a clinical response was 3.2 × 104 
CMV copies/mL of blood (range 1.4 × 103 – 3.44 × 105 copies). Following adoptive immunotherapy, 
the median viral load dropped to 1.2 × 103 CMV copies/mL of blood (range 0‒7.9 × 103 copies; Table 
4). Furthermore, many of these patients showed resolution of CMV disease symptoms (Table 4). 
More importantly, following the completion of adoptive T-cell therapy, the use of anti-viral drug 
therapy was either completely stopped (5/11) or significantly reduced (6/11; Table 4).  
 
Virological and immunological monitoring following T-cell therapy 
To assess the impact of adoptive T-cell therapy on CMV-specific T cell immune reconstitution, we 
conducted a longitudinal intracellular cytokine analysis following immunotherapy, and overlaid this 
analysis with virological monitoring in each patient. Representative data from eight patients, 
including seven who showed an objective response to adoptive immunotherapy, are shown in Fig. 2. 
The shaded box represents the analysis period pre-treatment and the arrows represent each 
infusion of autologous in vitro-expanded CMV-specific T cells. This analysis revealed evidence of 
immunological reconstitution post-therapy in association with control of viraemia. This is best 
exemplified in patient 1553PAH08, whose proportion of IFN-γ-producing CMV-specific T cells 
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increased from 0.03% prior to the first infusion to 9.3% at the completion of the follow-up period, 
with a concordant reduction in viral load and cessation of anti-viral drug therapy (Fig. 2A). A similar 
improvement in peripheral T-cell immunity following the commencement of T-cell infusions was also 
evident in other patients, including 1553PAH09, 1553PCH02 and 1553PCH04 (Fig. 2A). It is important 
to note that immune reconstitution in these patients was observed in spite of the continuation of 
immunosuppressive therapies prescribed prior to adoptive T-cell therapy (Table 1). Coincident with 
immune reconstitution, we also observed improvement in the functional quality of CMV-specific T-
cell responses, characterised by an increased proportion of T cells co-expressing IFN-γ, TNF and 
CD107 (Fig. 2B). In contrast, patient 1553RAH01, who did not respond clinically to therapy, showed 
no evidence of immunological reconstitution post-therapy. Patient 1553PCH01 experienced a 
decline in CMV-specific T cell immunity, coincident with contracting a secondary infection that 
caused bilateral bronchopneumonia. Follow-up immunological analysis was not possible for patient 
1553PCH03, who died early after the commencement of therapy due to complications related to 
CMV infection. Interestingly, although patients 1553PAH06 and 1553PCH05 showed clinical 
improvement, there was no change in the frequency of CMV-specific T cells in their peripheral blood 
following adoptive T-cell therapy. 
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Discussion  
In this study we describe the first formal evaluation of autologous CMV-specific T-cell therapy in SOT 
recipients. In a cohort of patients recruited due to evidence of drug resistance or intolerance, or 
persistent viral reactivation or disease, we demonstrate no evidence of severe adverse events or any 
negative impact on the graft following T-cell administration. While this study was not designed to 
access efficacy, we saw evidence of viral control following T-cell therapy in the majority of treated 
patients. This provides a platform to evaluate the potential efficacy of T-cell therapy in a larger 
cohort of SOT recipients, with the inclusion of a control arm.  
The therapeutic efficacy of donor-derived CMV-specific T-cell therapy in HSCT recipients has 
provided clear evidence of the potential therapeutic benefits of adoptive cell therapy in both 
preventing and treating viral disease in transplant patients [18, 19]. In contrast with CMV-specific T 
cells generated from healthy CMV-seropositive individuals for administration in HSCT recipients, 
which has now been administered to over 100 patients [20, 21], autologous CMV-specific 
immunotherapy in SOT recipients is dependent upon the capacity to generate CMV-specific T cells 
from immunosuppressed individuals. However, case reports in both SOT and HSCT recipients have 
shown its potential efficacy [10-13]. Consistent with these previous observations, we were able to 
generate CMV-specific T cells from 20 of the 21 patients for whom T-cell manufacture was 
attempted in the current study. Our observations indicate that despite the heavy 
immunosuppressive regimes used to prevent graft rejection, the majority of these individuals were 
able to prime a CMV-specific T-cell response and, in some cases, patients had a high precursor 
frequency in their PBMC prior to T-cell expansion. We did note functional defects in the CMV-
specific T cells in the peripheral blood of SOT recipients as recently reported [22], characterised by a 
reduced capacity to express TNF and IFN-γ, which could potentially mediate increased sensitivity to 
viral reactivation. Importantly, and likely due to the removal of these cells from the 
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immunosuppressive environment, this phenotype could be reversed following in vitro stimulation, 
with the majority of expanded CMV-specific T cells co-expressing CD107a, TNF and IFN-γ.  
Both virological and immunological monitoring provided evidence of the potential benefit 
that immunological reconstitution following adoptive immunotherapy can have upon viral control in 
SOT patients. Although the study was not designed to assess efficacy, and in some patients the 
changes were transient, there was evidence in multiple patients that immune reconstitution 
coincided with reduction in or resolution of viral reactivation. This is particularly important for the 
SOT recipients who had developed drug resistance or had either ongoing or a previous history of 
CMV-associated end-organ disease. Furthermore, we also showed that adoptive T-cell therapy can 
be safely used, concurrently with immunosuppressive therapies, for preventing CMV-associated 
complications in patients who are unable to tolerate standard anti-viral drug therapy.  
In summary, whilst efficacy needs to be confirmed in controlled trials, this prospective, 
multi-centre, open-label study has confirmed the feasibility and safety of CMV-targeted autologous 
adoptive T-cell therapy in SOT recipients. It therefore provides an important platform for subsequent 
controlled studies and for the future application of adoptive T-cell therapy in SOT recipients, 
especially in a setting where no appropriate treatment options are available.  
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Figure Legends 
 
Figure 1:  Phenotypic and functional characteristics of CMV-specific T cells expanded for 
adoptive immunotherapy. (A) The phenotypic characteristics of CMV peptide pool-
expanded T cells were assessed using standard TBNK analysis, measuring the surface 
expression of CD3 (T cells), CD8 (CD8+ T cells), CD4 (CD4+ T cells), CD16 and CD56 (NK 
cells) and CD19 (B cells). (B) PBMC (ex vivo) or cultured T cells (Day 14) were assessed 
for the intracellular production of IFN-γ following recall with the CMV peptide pool or 
with individual HLA-matched peptides. The data represent the proportion of CD8+ T 
cells producing IFN-γ. (C) Comparison of CMV-specific T cell responses generated from 
either kidney or heart/lung transplant patients (D) Comparison of CMV-specific T-cell 
responses generated from either CMV-seronegative recipients (R-) or CMV-seropositive 
recipients (R+). (E) CMV peptide pool-stimulated T cells were assessed for intracellular 
cytokine production (IFN-γ, TNF, IL-2) and degranulation (CD107a) following recall with 
the CMV peptide pool. The data represent the proportion of the total antigen-specific T 
cells producing each combination of effector functions. 
 
Figure 2:  Immunological and virological monitoring following adoptive cellular therapy. (A) 
PBMC samples from patients before and after T-cell therapy were assessed for IFN-γ-
producing CMV-specific T cells following stimulation with the CMV peptide pool. The 
data represent an overlay of the number of IFN-γ-producing CD8+ T cells and the CMV 
load in copies/mL from eight patients. The shaded area indicates the time period prior 
to adoptive T-cell therapy and the arrows represent T-cell infusions.  (B) Polyfunctional 
cytokine (IFN-γ, TNF, IL-2) and degranulation (CD107a) analysis was performed on PBMC 
samples following stimulation with the CMV peptide pool. Heat-maps represent the 
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proportion of total antigen-specific T cells producing each combination of effector 
functions. For 1553RAH01, polyfunctional analysis could not be performed due to the 
low level of CMV-specific T cell immunity. 
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Table 1:  Clinical profile of SOT recipients enrolled in the study 
Patient 
Code 
Age/ 
Sex 
Organ 
Criteria for 
Recruitment
a
 
Immuno-
suppression
 
Anti-Viral 
Treatment
 
Drug 
Resistance
 
CMV Disease 
History 
Donor/ 
Recipient 
CMV Status 
1553PAH01 61M Kidney B,C 
TAC; MMF; 
MePRD 
GCV; FOS; 
IVIG 
GCV
b 
Pan-enteritis
c
 +/- 
1553PAH02 45F Kidney A 
TAC; MMF; 
PRD 
VGCV Nil
d
 Colitis
c
 +/+ 
1553PAH03 57M Kidney A CSA; PRD VGCV; GCV Nil None Unk/+ 
1553PAH04 64F Kidney A 
TAC; MMF; 
PRD 
VGCV Nil Colitis
e 
+/+ 
1553PAH05 23M Kidney C 
TAC; MMF; 
PRD   
VGCV; GCV; 
FOS; LEF 
GCV
b
 
Colitis
c
 
Pneumonitis
e
 
+/+ 
1553PAH06 57M Kidney A 
TAC; MMF; 
PRD 
VGCV; GCV GCV Colitis
e
 -/- 
1553PAH07 26F Kidney A 
TAC; MMF; 
PRD 
VGCV; GCV Nil Colitis
e
  +/+ 
1553PAH08 26M Kidney B,C 
TAC; MMF; 
PRD 
VGCV; GCV; 
FOS 
Nil None +/- 
1553PAH09 44M Kidney C 
TAC; MMF; 
PRD; MePRD 
VGCV; GCV Nil None +/- 
1553PAH10 53F Kidney A 
TAC; MMF; 
PRD 
VGCV; GCV Nil None  +/+ 
1553PAH11 45M Kidney C 
TAC; MMF; 
PRD 
VGCV; GCV Nil None +/- 
1553PAH12 43F Kidney C 
TAC; MMF; 
PRD 
VGCV; GCV Nil Colitis
c
 +/- 
1553PAH13 53M Kidney A 
TAC; MMF; 
PRD 
VGCV; GCV Nil None +/+ 
1553PCH01 62M Lung B EVR, PRD  GCV; FOS GCV Oesophagitis
c
 -/- 
1553PCH02 55M Lung A 
TAC; MMF; 
EVR; AZA; 
PRD 
VGCV; GCV; 
FOS; IVIG 
GCV Colitis
c
 +/+ 
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1553PCH03 62F Lung C 
TAC; MMF; 
EVR; AZA; 
MYF 
VGCV; GCV; 
FOS; IVIG 
GCV, CDV Pneumonitis
c
 +/- 
1553PCH04 29F Lung A 
CSA; TAC; 
MMF; EVR 
VGCV: GCV; 
FOS; IVIG; 
LEF 
GCV 
Pneumonitis
c
 
Colitis
c
 
+/- 
1553PCH05 66M Lung A 
CSA; TAC; 
MMF; AZA 
VGCV; GCV  Nil 
Colitis
c 
Mouth ulcer
c 
+/- 
1553RAH01 64M Lung D  TAC; PRD 
VGCV; GCV; 
IVIG 
Nil Pneumonitis
c
 +/- 
SASRAH01 41F Lung A,B 
TAC; PRD; 
AZA; EVR; 
LEF; MePRD 
VGCV; GCV; 
FOS 
GCV; UL97; 
L595S 
Hepatitis
c 
Pneumonitis
c
 
+/- 
SASSVH01 56M Lung A,B NA 
VGCV: GCV; 
FOS; CDV 
GCV; L595S; 
FOS; UL54; 
L415N; 
S734P; 
I840T 
None +/- 
1553PCH06 61M Heart D CSA; MMF VGCV Nil None +/+ 
Abbreviations:  AZA, azathioprine; CDV, cidofovir; CSA, cyclosporin; EVR, everolimus; FOS, foscarnet; GCV, 
ganciclovir; LEF, leflunomide; MePRD, methylprednisolone; MMF, mycophenolate; NA, not available; PRD, 
prednisolone; TAC, tacrolimus; VGCV, valganciclovir. 
 
a
 A: CMV reactivation or disease (as defined by histology) following successful initial therapy; B: Persistent CMV 
disease, i.e. no response to 2 weeks of salvage foscarnet or other second line anti-viral agent; C: Persistent 
CMV replication (more than 6 weeks by PCR) despite appropriate anti-viral therapy; D: Any CMV reactivation 
or disease where anti-viral therapy is contraindicated on the basis of intolerance or end organ limitation (e.g. 
renal impairment, marrow dysfunction). 
b
 Clinical evidence of resistance, standard mutations not detected. 
c
 Histologically confirmed CMV disease. 
d
 Nil: No evidence of resistance.  
e
 Clinical diagnosis of CMV disease, not confirmed by histology. 
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Table 2:  CMV-specific reactivity of in vitro-expanded T cells from SOT recipients 
Patient Code 
Recipient HLA 
Type 
Donor HLA 
Type 
CMV-Specific T cell  
Response
a
 
CMV Epitopes Targeted 
Ex vivo Day 14 
1553PAH01 A1 A11 B8 B60 
A31 A33 B51 
B58 
0.24 0.0 NA 
1553PAH02 A2 A34 B44 B75 A1 A2 B44 B44 5.15 79.9 
NLV (pp65,  A2); VLE/YIL (IE-1, A2) 
DEL (IE-1, B44) 
1553PAH04 A2 A25 B7 B35 A2 A24 B7 B62 0.43 47.6 RPH (pp65, B7); TPR (pp65, B7) 
1553PAH05 
A24 A34 B56 Cw1 
Cw7 
A3 A31 B51 B7 0.05 24.3 QYD (pp65, A24) 
1553PAH06 A2 A32 B7 B27 A2 A11 B13 B46 17.67 77.2 
NLV (pp65, A2); RPH (pp65, B7); 
TPR (pp65, B7) 
1553PAH07 A2 A2 B44 B51 A2 A2 B7 B44 0 36.5 NLV (pp65, A2) 
1553PAH08 A1 A29 B8 B52 A1 A2 B44 B57 0 22.9 VTE (pp50, A1); ELR/K (IE-1, B8); 
1553PAH09 
A3 A29 B44 B45 
Cw6 Cw16 
A2 A3 B7 B51 0.09 48.4 TRA (pp65, Cw6) 
1553PAH10 
A11 A24 B7 B55 
Cw7 Cw7 
A2 A31 B62 B60 3.14 66.0 
RPH (pp65, B7); TPR (pp65, B7); 
QYD (pp65, A24); AYA (IE-1, A24) 
1553PAH11 A3 A24 B35 B60 A2 A23 B44 B62 3.21 59.1 IPS (pp65, B35); AYA (IE-1, A24) 
1553PAH12 A25 A68 B8 B35 A1 A11 B8 B35 0.44 61.6 IPS (pp65, B35); ELR/K (IE-1, B8) 
1553PAH13 
A2 A11 B35 B35 
Cw4 Cw4 
A11 A32 B58 
B62 Cw4 Cw7 
3.21 60.2 NLV (pp65, A2); IPS (pp65, B35) 
1553PCH01
b
 
A3 A31 B38 B65 
Cw8 
A2 A3 B7 B65 0.00 56.9 KAR (IE-1; A31) 
1553PCH02 
A1 A3 B42 B57 
Cw17 
A2 A3 B7 B62 0.87 57.3 TRA (pp65, Cw6);  VTE (pp50, A1) 
1553PCH03 
A1 A3 B7 B8 Cw7 
Cw7 
A1 A2 B51 B57 8.74 48.0 
RPH (pp65, B7); TPR (pp65, B7);   
YSE (pp65, A1); VTE (pp50; A1);   
QIK (IE-1; B8); CRV (IE-1; Cw7) 
1553PCH04 
A2 A11 B44 B50 
Cw5 Cw6 
A32 A62 B44 
B53 
6.35 63.6 TRA (pp65, Cw6) 
1553PCH05 
A2 A3 B27 B49 
Cw1 Cw7 
A3 A29 B50 B51 1.32 26.9 NLV (pp65, A2) 
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1553RAH01 A2 A23 B44 B44 NA 0.00 31.9 NA 
SASRAH01
c
 
A1 A11 B7 B35 
Cw4 Cw7 
NA 0.73 11.68 
RPH (pp65, B7); TPR (pp65, B7);   
YSE (pp65, A1); VTE (pp50, A1);    
IPS (pp65, B35); 
SASSVH01
c
 
A1 A3 B7 B8 Cw7 
Cw7 
NA 14.22 43.94 
RPH (pp65, B7); TPR (pp65, B7);  
VTE (pp50; A1); ELR (IE-1; B8);     
QIK (IE-1; B8); 
1553PCH06 
A2 A24 B44 B56 
Cw1 Cw5 
A1 A3 B7 B8 17.13 71.4 NLV (pp65, A2); VLE/YIL (IE-1, A2) 
Abbreviations:  NA, not available 
a
 CMV responses were determined as the proportion of CD8
+
 T cells producing IFN-γ 
b
 The KAR peptide was added to the CMV peptide pool for stimulation  
c
 HLA-specific peptide pools were generated to manufacture T cells for these patients 
Downloaded from https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciy549/5049442
by University of Queensland Library user
on 20 July 2018
  24 
 
 
Table 3: Safety assessment after T-cell therapy 
Adverse events
a
 
Number of 
incidents 
Frequency of 
occurrence
b
 
Grade 1 – Mild   
      Nausea  2 1 (8%) 
      Malaise  2 1 (8%) 
      Fatigue  2 1 (8%) 
      Altered taste sensation 2 1 (8%) 
Grade 2 – Moderate   
      Fatigue 1 1 (8%) 
      Halitosis 1 1 (8%) 
      Microangiopathic haemolytic anaemia  1 1 (8%) 
a
 Events possibly or probably related to the T-cell therapy. No adverse events were deemed to be definitely 
related to the T-cell therapy.  
b
 Number of patients who received T cell therapy and experienced the adverse event.  
 
Downloaded from https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciy549/5049442
by University of Queensland Library user
on 20 July 2018
  25 
Table 4:  Clinical responses following adoptive T-cell therapy 
Patient 
Code 
Organ 
Timing of 
First Infusion 
Post-
Transplant 
(days)  
No. of 
Infusions 
Total T-
cell Dose 
(×10
6
) 
Peak CMV 
Load Pre-
Infusion 
(×10
3
) 
CMV Load 
at First 
Infusion 
(×10
3
) 
Peak CMV 
Load Post-
Infusion 
(×10
3
) 
Anti-Viral 
Therapy Pre-
Infusion 
Anti-Viral 
Therapy 
Post-
Infusion 
Clinical Symptoms/ 
Management Post-Infusion 
1553PAH05 Kidney 411 1 45.25 1.4 0.32 0.32 
VGCV; GCV; 
FOS; LEF 
FOS; LEF
a
 
DNAemia and CMV disease 
symptoms resolved 
1553PAH06 Kidney 262 6 245 12 0.13 0.78 VGCV; GCV Nil 
DNAemia and CMV disease 
symptoms resolved 
1553PAH08 Kidney 187 5 226 54 2.8 7.9 
VGCV; GCV; 
FOS 
VGCV; 
IVIG 
Reduction in DNAemia and 
resolution of CMV disease 
symptoms 
1553PAH09 Kidney 237 5 180 10 0 1.4 VGCV; GCV VGCV 
Diarrhoea resolved; 
immunosuppression 
reduced 
1553PCH01 Lung 3403 6 210 8 0 0.12 GCV; FOS Nil 
FOS stopped without viral 
reactivation 
1553PCH02 Lung 724 3 108 48 0 2.3 
VGCV; GCV; 
FOS; IVIG 
Nil Reduction in DNAemia 
1553PCH03 Lung 1480 2 42 12 24 45 
VGCV; GCV; 
FOS; IVIG 
GCV Died of multi-organ failure 
1553PCH04 Lung 979 6 168 17 4.7 2.9 
VGCV; GCV; 
FOS; IVIG; LEF 
IVIG; LEF Reduction in DNAemia 
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1553PCH05 Lung 1075 6 241 47 0 0 VGCV; GCV VGCV Reduction in DNAemia 
1553RAH01 Lung 861 3 104 18.9 1.3 17.6 VGCV; GCV 
GCV; FOS; 
IVIG 
Ongoing elevated CMV PCR, 
however no end-organ 
disease 
SASRAH01 Lung 266 4 120 344 0 1 
VGCV; GCV; 
FOS 
Nil 
Drug-independent 
resolution of DNAemia 
SASSVH01
b
 Lung 790 
2 
1 
38.7 
(cycle 1) 
22.2 
(cycle 2) 
95.4 1.8 2.5  
VGCV; GCV; 
FOS; CDV 
CDV Reduction in DNAemia 
1553PCH06 Heart 637 6 204 1.5 0 0 VGCV Nil 
VGCV ceased after T cell 
therapy 
Abbreviations: CDV, cidofovir; FOS, foscarnet; GCV, ganciclovir; IVIG, intravenous CMV immunoglobulin; LEF, leflunomide; VGCV, valganciclovir. 
a
 Used as part of CMV treatment due to its antiviral activity.  
b
 This patient received two cycles of T-cell therapy.  
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